Skip NavigationSkip to Content

NCI at Frederick Scientific Publications Advanced Search

Search

  1. NCI-F Publications

  2. Return to Quick Search
Search
  2. Year Published:

Your search returned 15 results.
User Information
Export Records
  1. 1.   TEM8/ANTXR1 Blockade Inhibits Pathological Angiogenesis and Potentiates Tumoricidal Responses against Multiple Cancer Types
  2. Chaudhary, A.; Hilton, M. B.; Seaman, S.; Haines, D. C.; Stevenson, S.; Lemotte, P. K.; Tschantz, W. R.; Zhang, X. Y. M.; Saha, S.; Fleming, T.; St Croix, B.
  3. Cancer Cell. 2012, Feb; 21(2): 212-226.
  1. 2.   Vascular endothelial growth factor receptor 2 inhibition in-vivo affects tumor vasculature in a tumor type-dependent way and downregulates vascular endothelial growth factor receptor 2 protein without a prominent role for miR-296
  2. Langenkamp, E.; Zwiers, P. J.; Moorlag, H. E.; Leenders, W. P.; Croix, B. S.; Molema, G.
  3. Anti-Cancer Drugs. 2012, Feb; 23(2): 161-172.
  1. 3.   The novel Akt inhibitor Palomid 529 (P529) enhances the effect of radiotherapy in prostate cancer
  2. Diaz, R.; Nguewa, P. A.; Diaz-Gonzalez, J. A.; Hamel, E.; Gonzalez-Moreno, O.; Catena, R.; Serrano, D.; Redrado, M.; Sherris, D.; Calvo, A.
  3. British Journal of Cancer. 2009 100(6): 932-940.
  1. 4.   Therapeutic Vulnerability of an In Vivo Model of Alveolar Soft Part Sarcoma (ASPS) to Antiangiogenic Therapy
  2. Vistica, D. T.; Hollingshead, M.; Borgel, S. D.; Kenney, S.; Stockwin, L. H.; Raffeld, M.; Schrump, D. S.; Burkett, S.; Stone, G.; Butcher, D. O.; Shoemaker, R. H.
  3. Journal of Pediatric Hematology Oncology. 2009 31(8): 561-570.
  1. 5.   Expression of hypoxia-inducible factor 1 alpha, hypoxia-inducible factor 2 alpha, and von Hippel-Lindau protein in epitheLiaL ovarian neoplasms and allelic loss of von Hippel-Lindau gene: nuclear expression of hypoxia-inducible factor 1 alpha is an independent prognostic factor in ovarian carcinoma
  2. Osada, R.; Horiuchi, A.; Kikuchi, N.; Yoshida, J.; Hayashi, A.; Ota, M.; Katsuyama, Y.; Melilo, G.; Konishi, I.
  3. Human Pathology. 2007, Sep; 38(9): 1310-1320.
  1. 6.   Modulation of angiogenesis by dithiolethione-modified NSAIDs and valproic acid
  2. Isenberg, J. S.; Jia, Y.; Field, L.; Ridnour, L. A.; Sparatore, A.; Del Soldato, P.; Sowers, A. L.; Yeh, G. C.; Moody, T. W.; Wink, D. A.; Ramchandran, R.; Roberts, D. D.
  3. British Journal of Pharmacology. 2007, May; 151(1): 142-151.
  1. 7.   Tumor endothelial marker 1 (Tem1) functions in the growth and progression of abdominal tumors
  2. Nanda, A.; Karim, B.; Peng, Z. S.; Liu, G. S.; Qiu, W. P.; Gan, C.; Vogelstein, B.; St Croix, B.; Kinzler, K. W.; Huso, D. L.
  3. Proceedings of the National Academy of Sciences of the United States of America. 2006, FEB 28; 103(9): 3351-3356.
  1. 8.   Echinomycin, a small-molecule inhibitor of hypoxia-inducible factor-1 DNA-binding activity
  2. Kong, D. H.; Park, E. J.; Stephen, A. G.; Calvani, M.; Cardellina, J. H.; Monks, A.; Fisher, R. J.; Shoemaker, R. H.; Melillo, G.
  3. Cancer Research. 2005, OCT 1; 65(19): 9047-9055.
  1. 9.   Molecular alterations in primary prostate cancer after androgen ablation therapy
  2. Best, C. J. M.; Gillespie, J. W.; Yi, Y. J.; Chandramouli, G. V. R.; Perlmutter, M. A.; Gathright, Y.; Erickson, H. S.; Georgevich, L.; Tangrea, M. A.; Duray, P. H.; Gonzalez, S.; Velasco, A.; Linehan, W. M.; Matusik, R. J.; Price, D. K.; Figg, W. D.; Emmert-Buck, M. R.; Chuaqui, R. F.
  3. Clinical Cancer Research. 2005, OCT 1; 11(19, Part 1): 6823-6834.
  1. 10.   Identification of a binding partner for the endothelial cell surface proteins TEM7 and TEM7R
  2. Nanda, A.; Buckhaults, P.; Seaman, S.; Agrawal, N.; Boutin, P.; Shankara, S.; Nacht, M.; Teicher, B.; Stampfl, J.; Singh, S.; Vogelstein, B.; Kinzler, K. W.; Croix, B. S.
  3. Cancer Research. 2004, DEC 1; 64(23): 8507-8511.
  1. 11.   TEM8 interacts with the cleaved C5 domain of collagen alpha 3(VI)
  2. Nanda, A.; Carson-Walter, E. B.; Seaman, S.; Barber, T. D.; Stampfl, J.; Singh, S.; Vogelstein, B.; Kinzler, K. W.; St Croix, B.
  3. Cancer Research. 2004 64(3): 817-820.
  1. 12.   Tumor endothelial markers: new targets for cancer therapy
  2. Nanda, A.; St Croix, B.
  3. Current Opinion in Oncology. 2004, JAN; 16(1): 44-49.
  1. 13.   Justified chauvinism: advances in defining meiotic recombination through sperm typing
  2. Carrington, M.; Cullen, M.
  3. Trends in Genetics. 2004 20(4): 196-205.
  1. 14.   The thioredoxin redox inhibitors 1-methylpropyl 2-imidazolyl disulfide and pleurotin inhibit hypoxia-induced factor 1 alpha and vascular endothelial growth factor formation
  2. Welsh, S. J.; Williams, R. R.; Birmingham, A.; Newman, D. J.; Kirkpatrick, D. L.; Powis, G.
  3. Molecular Cancer Therapeutics. 2003 2(3): 235-243.
  1. 15.   Identification of small molecule inhibitors of hypoxia- inducible factor 1 transcriptional activation pathway
  2. Rapisarda, A.; Uranchimeg, B.; Scudiero, D. A.; Selby, M.; Sausville, E. A.; Shoemaker, R. H.; Melillo, G.
  3. Cancer Research. 2002 62(15): 4316-4324.
NCI at Frederick

You are leaving a government website.

This external link provides additional information that is consistent with the intended purpose of this site. The government cannot attest to the accuracy of a non-federal site.

Linking to a non-federal site does not constitute an endorsement by this institution or any of its employees of the sponsors or the information and products presented on the site. You will be subject to the destination site's privacy policy when you follow the link.

ContinueCancel